| Pembrolizumab with or without radiation therapy for metastatic non-small cell lung cancer: a randomized phase I/II trial J Welsh, H Menon, D Chen, V Verma, C Tang, M Altan, K Hess, ... Journal for immunotherapy of cancer 8 (2), 2020 | 178 | 2020 |
| Role of radiation therapy in modulation of the tumor stroma and microenvironment H Menon, R Ramapriyan, TR Cushman, V Verma, HH Kim, ... Frontiers in immunology 10, 193, 2019 | 133 | 2019 |
| Low-dose radiation treatment enhances systemic antitumor immune responses by overcoming the inhibitory stroma HB Barsoumian, R Ramapriyan, AI Younes, MS Caetano, H Menon, ... Journal for immunotherapy of cancer 8 (2), 2020 | 132 | 2020 |
| Altered cancer metabolism in mechanisms of immunotherapy resistance R Ramapriyan, MS Caetano, HB Barsoumian, ACP Mafra, EP Zambalde, ... Pharmacology & therapeutics 195, 162-171, 2019 | 130 | 2019 |
| Role of miRNAs in immune responses and immunotherapy in cancer MA Cortez, S Anfossi, R Ramapriyan, H Menon, SC Atalar, M Aliru, ... Genes, Chromosomes and Cancer 58 (4), 244-253, 2019 | 129 | 2019 |
| Influence of low-dose radiation on abscopal responses in patients receiving high-dose radiation and immunotherapy H Menon, D Chen, R Ramapriyan, V Verma, HB Barsoumian, ... Journal for immunotherapy of cancer 7, 1-9, 2019 | 107 | 2019 |
| Phase II trial of ipilimumab with stereotactic radiation therapy for metastatic disease: outcomes, toxicities, and low-dose radiation–related abscopal responses JW Welsh, C Tang, P De Groot, A Naing, KR Hess, JV Heymach, ... Cancer immunology research 7 (12), 1903-1909, 2019 | 101 | 2019 |
| Phase I trial of pembrolizumab and radiation therapy after induction chemotherapy for extensive-stage small cell lung cancer JW Welsh, JV Heymach, D Chen, V Verma, TR Cushman, KR Hess, ... Journal of Thoracic Oncology 15 (2), 266-273, 2020 | 71 | 2020 |
| Response and outcomes after anti-CTLA4 versus anti-PD1 combined with stereotactic body radiation therapy for metastatic non-small cell lung cancer: retrospective analysis of … D Chen, H Menon, V Verma, C Guo, R Ramapriyan, H Barsoumian, ... Journal for immunotherapy of cancer 8 (1), 2020 | 71 | 2020 |
| Phase 1/2 trial of pembrolizumab and concurrent chemoradiation therapy for limited-stage SCLC JW Welsh, JV Heymach, C Guo, H Menon, K Klein, TR Cushman, ... Journal of Thoracic Oncology 15 (12), 1919-1927, 2020 | 67 | 2020 |
| SHP-2 and PD-L1 inhibition combined with radiotherapy enhances systemic antitumor effects in an anti–PD-1–resistant model of non–small cell lung cancer D Chen, HB Barsoumian, L Yang, AI Younes, V Verma, Y Hu, H Menon, ... Cancer immunology research 8 (7), 883-894, 2020 | 66 | 2020 |
| Results of a phase 1/2 trial of chemoradiotherapy with simultaneous integrated boost of radiotherapy dose in unresectable locally advanced esophageal cancer D Chen, H Menon, V Verma, SN Seyedin, JA Ajani, WL Hofstetter, ... JAMA oncology 5 (11), 1597-1604, 2019 | 65 | 2019 |
| Triple therapy with MerTK and PD1 inhibition plus radiotherapy promotes abscopal antitumor immune responses MS Caetano, AI Younes, HB Barsoumian, M Quigley, H Menon, C Gao, ... Clinical Cancer Research 25 (24), 7576-7584, 2019 | 50 | 2019 |
| IDO1 inhibition overcomes radiation-induced “rebound immune suppression” by reducing numbers of IDO1-expressing myeloid-derived suppressor cells in the tumor microenvironment A Li, HB Barsoumian, JE Schoenhals, MS Caetano, X Wang, H Menon, ... International Journal of Radiation Oncology* Biology* Physics 104 (4), 903-912, 2019 | 43 | 2019 |
| Bone morphogenetic protein 7 promotes resistance to immunotherapy MA Cortez, F Masrorpour, C Ivan, J Zhang, AI Younes, Y Lu, MR Estecio, ... Nature communications 11 (1), 4840, 2020 | 35 | 2020 |
| Complications and adverse events of plaque brachytherapy for ocular melanoma K Peddada, R Sangani, H Menon, V Verma Journal of contemporary brachytherapy 11 (4), 392-397, 2019 | 34 | 2019 |
| High plus low dose radiation strategy in combination with TIGIT and PD1 blockade to promote systemic antitumor responses HB Barsoumian, D Sezen, H Menon, AI Younes, Y Hu, K He, ... Cancers 14 (1), 221, 2022 | 26 | 2022 |
| Rescue of immunotherapy-refractory metastatic merkel cell carcinoma with conventionally fractionated radiotherapy and concurrent pembrolizumab BC Bloom, A Augustyn, TA Pezzi, H Menon, LL Mayo, SJ Shah, ... Frontiers in oncology 9, 223, 2019 | 24 | 2019 |
| High GILT expression and an active and intact MHC class II antigen presentation pathway are associated with improved survival in melanoma KH Buetow, LR Meador, H Menon, YK Lu, J Brill, H Cui, DJ Roe, ... The Journal of Immunology 203 (10), 2577-2587, 2019 | 23 | 2019 |
| Addition of TLR9 agonist immunotherapy to radiation improves systemic antitumor activity AI Younes, HB Barsoumian, D Sezen, V Verma, R Patel, M Wasley, Y Hu, ... Translational Oncology 14 (2), 100983, 2021 | 22 | 2021 |
